Holen Sie sich die Stockscreener-App
8.57
5.62%
-0.51
Handel nachbörslich:
8.60
0.03
+0.35%
Regenxbio Inc Aktie (RGNX) Neueste Nachrichten
Regenxbio Reinforces Case for Its Duchenne Gene Therapy Amid Accelerated Approval Uncertainty - Citeline News & Insights
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Positive interim data for Regenxbio’s gene therapy in DMD - The Pharmaletter
Stifel cuts Regenxbio stock price target to $42 on gene therapy data - Investing.com Nigeria
Insider Sell Alert: Steve Pakola Sells Shares of Regenxbio Inc (RGNX) - GuruFocus
Pakola Steve, Regenxbio CMO, sells $53k in RGNX stock - Investing.com Nigeria
MDA: Vinay away, AA in play for Regenxbio gene therapy? - BioWorld MedTech
Stifel reiterates Regenxbio stock rating on Duchenne trial data - Investing.com
Stifel reiterates Regenxbio stock rating on Duchenne trial data By Investing.com - Investing.com Canada
ROSEN, A RANKED AND LEADING FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - Black Hills Pioneer
ROSEN, A RANKED AND LEADING FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Regenxbio Says Its Gene Therapy For Muscle Disorder Showed No Evidence Of Liver Injury In Study - Stocktwits
Regenxbio reports positive interim data for Duchenne gene therapy By Investing.com - Investing.com Nigeria
Regenxbio reports positive interim data for Duchenne gene therapy - Investing.com Australia
REGENXBIO (RGNX) Reports Promising Interim Results for Duchenne Gene Therapy - GuruFocus
Regenxbio reports new positive interim data from phase I/II Affinity Duchenne® trial of RGX-202 - marketscreener.com
REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 - PR Newswire
RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - The Malaysian Reserve
Lab Cells Built Different And Therefore Patentable - marketscreener.com
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Investors who lost money on REGENXBIO Inc.(RGNX) should contact Levi & Korsinsky about pending Class ActionRGNX - Morningstar
What is HC Wainwright's Estimate for REGENXBIO Q1 Earnings? - MarketBeat
Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN
RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP - pharmiweb.com
REGENXBIO Inc. (NASDAQ: RGNX) Investor Alert: Lawsuit seeks to recover Losses for Investors - openPR.com
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Investors who lost money on REGENXBIO Inc.(RGNX) should contact The Gross Law Firm about pending Class ActionRGNX - PR Newswire
Regenxbio stock: Clear Street reiterates Buy on gene therapy data - Investing.com Nigeria
(RGNX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
RGNX'S "Transformational" Promise Became a $2.40 Loss for Investors: Levi & Korsinsky, LLP - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors - WFMZ.com
REGENXBIO (NASDAQ:RGNX) Shares Gap UpTime to Buy? - MarketBeat
Regenxbio at Leerink Global Healthcare Conference: Strategic Pipeline Advancements - Investing.com Nigeria
Regenxbio at Leerink Global Healthcare Conference: Strategic Pipeline Advancements By Investing.com - Investing.com Canada
H.C. Wainwright cuts Regenxbio stock price target to $30 - Investing.com India
H.C. Wainwright cuts Regenxbio stock price target to $30 By Investing.com - Investing.com UK
HC Wainwright Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price - MarketBeat
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Regenxbio (RGNX): HC Wainwright Maintains Rating, Lowers Price T - GuruFocus
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - PR Newswire
REGENXBIO commends women leadership driving mission on International Womens Day - Traders Union
ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - Bluefield Daily Telegraph
ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 Earnings Call Transcript - Insider Monkey
Why REGENXBIO Inc. stock remains a top recommendation2026 Chart Watch & AI Based Trade Execution Alerts - Naître et grandir
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
RBC Capital Reaffirms Their Buy Rating on RegenXBio (RGNX) - The Globe and Mail
RegenXbio Faces FDA Clinical Holds: Heightened Development Risk, Potential Delays, and Investor Uncertainty - TipRanks
REGENXBIO Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm ... - Bluefield Daily Telegraph
REGENXBIO Inc. Sued for Securities Law Violations – - GlobeNewswire
Team powers gene therapy mission, REGENXBIO asserts - Traders Union
The Analyst Verdict: Regenxbio In The Eyes Of 8 Experts - Benzinga
Assessing Where Regenxbio Stands After FY25 Results (NASDAQ:RGNX) - Seeking Alpha
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026 - PR Newswire
Regenxbio: Q4 Earnings Snapshot - theheraldreview.com
Regenxbio Inc earnings missed by $0.58, revenue fell short of estimates - Investing.com Australia
REGENXBIO Q4 Earnings Call Highlights - MarketBeat
REGENXBIO outlines 2026 Duchenne, wet AMD, and diabetic retinopathy milestones while targeting pivotal data releases - MSN
RegenXBio Earnings Call Balances Gene Therapy Risks - TipRanks
REGENXBIO (RGNX) Eyes Key Developments in 2026 Amid Robust Pipel - GuruFocus
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):